ERBB2 and cancer: Untreated, unresectable, non-HER2-positive G/GEJ cancer, and esophageal adenocarcinoma. 69.5% male, 39% with age ≥ 65, 41.5% ECOG 0, 22.5% from Asia, 17% from the USA and Canada, and 61% from other regions.